Key Teaching Points
•
The Abbott Aveir DR is the first and only dual-chamber leadless pacemaker available
for implantation. The atrial and ventricular leadless pacemakers are paired with implant-to-implant
(i2i) communication, which occurs beat-by-beat via wireless transmission of subthreshold
electrical signals.
•
With loss and recovery of i2i communication, there are compensatory switches in functional
pacing modes that occur beat-by-beat to maintain atrioventricular synchrony (atrial
tracking and/or pacing) when possible and provide uninterrupted ventricular demand
pacing.
•
We present an electrocardiogram from the first reported patient post–orthotopic heart
transplant who received the Aveir DR, demonstrating changes in functional pacing modes
during the intermittent loss of ventricular-to-atrial i2i communication.
•
Owing to novel programming and function of dual-chamber leadless pacemakers, clinicians
must recognize and interpret previously undescribed ECG patterns to distinguish normal
vs abnormal pacemaker behavior.
Introduction
The Abbott Aveir™ DR (Abbott, Park, IL) is the first and only dual-chamber leadless
pacemaker, and was recently approved by the U.S. Food and Drug Administration on July
5, 2023. Prior leadless pacemakers include the Medtronic Micra™ VR and the Abbott
Aveir VR single-chamber leadless pacemakers, which provide VVI(R) pacing capability,
and the Medtronic Micra AV single-chamber leadless pacemaker with atrial-synchronous
VDD(R) pacing via tracking of mechanical atrial contraction.
1
,
2
The Aveir leadless pacemakers are unique in that they allow for mapping of intracardiac
electrical measurements (including assessment of current of injury) before device
deployment in order to reduce the number of repositioning attempts, and their active
fixation helix enables safe and successful chronic retrieval.
2
The Aveir DR dual-chamber leadless pacemaker optimizes atrioventricular (AV) synchrony
by providing atrial pacing, expanding the options for patients who require DDD(R)
pacing and for whom the potential complications of conventional transvenous pacemakers
are undesired or prohibitive to implantation.
The development of a dual-chamber leadless pacemaker with DDD(R) pacing and wireless
communication between separate atrial and ventricular devices has required the innovation
of unique device programming and pacing behavior. The Aveir DR atrial and ventricular
pacemakers are paired at implant with implant-to-implant (i2i) communication, which
occurs beat-by-beat via transmission of subthreshold electrical signals through blood
and myocardium between the atrial and ventricular devices to provide AV synchrony
and uninterrupted ventricular pacing.
3
,
4
The i2i communication can be interrupted in different directions with consequent changes
in pacing behavior. Of note, i2i communication may improve with long-term observation
in Aveir DR recipients. Position changes may transiently affect i2i communication.
Furthermore, hospital equipment (eg, the Philips electrocardiogram [ECG] patient monitoring
systems, external defibrillators) may interfere with i2i communication while connected,
with restoration of i2i on equipment removal (Personal communication, Abbott Medical,
Park, IL).
With the loss of i2i communication between Aveir DR atrial and ventricular leadless
pacemakers, there is a compensatory switch in functional pacing mode to an “automatic
safeguard mode” to maintain AV synchrony (atrial tracking and/or pacing) when possible
and provide uninterrupted ventricular demand pacing (Figure 1).
3
,
4
Atrial-to-ventricular (A2V) communication is required for atrial tracking and thus
atrial-triggered ventricular pacing. Ventricular-to-atrial (V2A) communication is
required to pace the atrium at the appropriate ventriculoatrial interval in the absence
of intrinsic atrial activity. In a patient with a dual-chamber Aveir DR leadless pacemaker,
intact A2V and V2A communication allows for DDD(R) pacing. With the loss of A2V i2i
communication, triggered ventricular pacing is not possible and the device mode switches
to DDI(R). With the loss of V2A i2i communication, atrial pacing is withheld, and
the pacing mode switches to VDD(R). With simultaneous loss of both A2V and V2A i2i
communication, the functional pacing mode becomes VDI(R), with the atrial leadless
pacemaker programmed OAO and the ventricular leadless pacemaker programmed VVI(R).
Because i2i communication is assessed beat-by-beat, these changes in functional pacing
modes during i2i loss can occur rapidly on a beat-by-beat basis. Whether AV synchrony
is preserved depends on the patient’s underlying rate and rhythm. For example, DDI
can provide AV synchrony when atrial pacing is required but cannot track intrinsic
atrial activity. VDD can provide AV synchrony by tracking intrinsic atrial activity
but cannot provide atrial pacing or AV synchrony in the setting of sinus bradycardia
or arrest. Importantly, regardless of the direction and duration of i2i interruption,
ventricular demand pacing will continue.
Figure 1
Functional pacing modes (automatic safeguard modes) during i2i loss in the Aveir™
DR dual-chamber leadless pacemaker (Abbott, Park, IL).
3
,
4
The Aveir DR is uniquely programmed to switch functional pacing modes with interruption
of implant-to-implant (i2i) communication between the atrial leadless pacemaker (aLP)
and ventricular leadless pacemaker (vLP). In a device programmed DDD, the diagram
outlines the automatic safeguard modes in the event of atrial-to-ventricular (A2V)
and/or ventricular-to-atrial (V2A) interruption. Check mark indicates intact i2i communication;
x mark indicates loss of i2i communication.
We present an ECG demonstrating the unique programming and pacing features of the
Aveir DR. This ECG is from the first reported patient post–orthotopic heart transplant
who received the Aveir DR as part of the Abbott Aveir Dual-Chamber Leadless i2i IDE
clinical trial, conducted at Advocate Aurora St. Luke’s Medical Center in Milwaukee,
Wisconsin.
5
Case Report
The patient is a 43-year-old man with a history of nonischemic cardiomyopathy and
an ejection fraction of 5%–10%, who presented with cardiogenic shock. He underwent
an orthotopic heart transplant with modified biatrial anastomosis. Post-transplant,
he had sinus node dysfunction and symptomatic chronotropic incompetence managed with
terbutaline, which caused new-onset atrial fibrillation. A dual-chamber pacemaker
was recommended owing to his dependency on terbutaline for adequate heart rates. The
advantages of a leadless pacemaker compared to a conventional transvenous device for
our patient, who is young and on chronic immunosuppressive therapy, include a decreased
risk of infection; absence of chronic indwelling leads, which predispose to subclavian
vein stenosis and occlusion; and the ability to retrieve the device in the future.
The Aveir DR was implanted as part of a clinical trial. Multiple post-transplant ECGs
demonstrated dual P waves at different sinus rates, representing dissociated atrial
depolarizations originating from recipient tissue and donor atrial depolarizations
that conducted to the ventricles. During device implantation, it was challenging to
select the best atrial location for deployment to ensure selective and accurate sensing
and tracking of donor P waves.
After deployment and sensitivity programming, both the atrial and ventricular leadless
pacemakers were paired successfully with i2i communication. The final interrogation
showed an atrial threshold of 2.5 V at 0.4 ms, sensing at 1.0 mV, and impedance of
320 ohms; and a ventricular threshold of 0.5 V at 0.4 ms, sensing at 9.1 mV, and impedance
of 1210 ohms. The devices were programmed DDD(R) at a rate of 60–120 beats per minute
(bpm).
On postimplant day 1, the dual-chamber leadless pacemaker interrogation showed 55%
atrial pacing, 9% ventricular pacing, 69% V2A i2i communication, and 90% A2V i2i communication.
Electrocardiogram
An ECG from postimplant day 1 demonstrates device programming and behavior when i2i
interruption occurs (Figures 1 and 2). The possibility of an automatic mode-switching
episode was excluded by device interrogation.
Figure 2
Electrocardiogram demonstrating changes in functional pacing modes with intermittent
ventricular-to-atrial (V2A) i2i loss. ∗ = Atrial-paced ventricular-paced (APVP) and
atrial-paced ventricular-sensed (APVS) PQRS complexes indicating brief restoration
of V2A implant-to-implant (i2i) communication. APVP complex is a fusion beat of intrinsic
and paced QRS. This electrocardiogram was obtained 1 day after Aveir DR (Abbott, Park,
IL) implant in a heart transplant recipient. It shows sinus rhythm with dual donor
and recipient P waves (blue arrows: donor P waves, sensed and tracked by the leadless
pacemaker; red arrows: recipient P waves from electrically dissociated remnant atrial
tissue). There is progressive fusion of intrinsic and ventricular-paced QRS complexes
with shortening PR intervals, as the V-paced rate is faster than the intrinsic sinus
and native QRS rate. Atrial tracking cannot be detected when the intrinsic atrial
rate is slower than the base V-pacing rate. Therefore, we cannot prove atrial-to-ventricular
communication. This electrocardiogram demonstrates changes in functional pacing modes
during V2A i2i loss, with brief restoration of V2A i2i for 2 PQRS complexes (∗). The
device is programmed DDD(R) 60–120 beats per minute (bpm), with both paced and sensed
atrioventricular (AV) delays of 200 ms, and additional ventricular intrinsic preference
(VIP) extension of 150 ms. The sensor-driven rate is ∼71 bpm; thus pacing cycle length
is 840 ms. Programmed ventriculoatrial interval = sensor-driven base rate (840 ms)
– AV delay (200 ms) – VIP extension (150 ms) = 490 ms. V-pacing (at pacing cycle length
840 ms) without A-pacing, with progressive QRS fusion, suggests VDI(R) or VDD(R) pacing
owing to a loss of V2A i2i. On the first marked PQRS complex (∗), A-pacing occurs
at the programmed VA interval (490 ms), suggesting a switch to DDI(R) or DDD(R) (at
same pacing cycle length, 840 ms) and thus restoration of V2A i2i. After these 2 complexes
(∗), V2A i2i is lost again, with pacing mode switching back to VDI(R) or VDD(R), again
at the same pacing cycle length (840 ms).
The ECG shows donor sinus P waves with associated QRS complexes and recipient P waves
originating from electrically dissociated remnant atrial tissue. There is progressive
fusion of intrinsic and ventricular-paced QRS complexes across the ECG with shortening
PR intervals, as the ventricular-paced rate is faster than the intrinsic sinus (and
associated intrinsic ventricular) rate. Owing to rate-responsive pacing in this device
programmed DDD(R) 60–120 bpm, the sensor has increased the pacing rate from a base
rate of 60 bpm to a sensor-driven rate of ∼71 bpm (840 ms). The presence or absence
of atrial tracking cannot be assessed when the intrinsic atrial rate is slower than
the sensor-driven base ventricular pacing rate. Therefore, we cannot determine whether
A2V communication is intact or interrupted (loss of A2V would preclude atrial tracking).
This ECG demonstrates changes in functional pacing modes with intermittent V2A loss.
With interruption of V2A communication, the system will not pace the atrium, and the
pacing mode will switch to VDI (if simultaneous A2V loss) or VDD (with A2V intact).
With restoration of V2A communication, the device can pace both the atrium and the
ventricle, and the pacing mode will switch to DDI (with simultaneous A2V loss) or
DDD (with A2V intact).
This ECG was obtained during interruption of V2A i2i communication, with brief restoration
of V2A communication for 2 PQRS complexes (asterisks). Ventricular (and not atrial)
pacing with progressive QRS fusion suggests VDI(R) or VDD(R) pacing owing to a loss
of V2A i2i communication. On the first PQRS complex marked by asterisks, atrial pacing
occurs at the end of the programmed ventriculoatrial interval (490 ms), suggesting
a switch in pacing mode to either DDI(R) or DDD(R) (at the same cycle length, 840
ms) and thus a restoration of V2A i2i. After these A-paced V-paced and A-paced V-sensed
complexes (asterisks), V2A i2i communication is lost again, with pacing mode switching
back to VDI(R) or VDD(R). The duration between the last sensed ventricular beat (second
asterisk) and the next paced ventricular complex remains at the same cycle length
of 840 ms.
On follow-up 23 days post–pacemaker implant, the patient was doing well, without cardiac
symptoms or postprocedural complications. He required 76% atrial pacing and 7% ventricular
pacing. V2A i2i communication was 89%, and A2V i2i was 91%. It should be noted that
V2A i2i communication, which was shown to be interrupted on ECG on postimplant day
1, significantly improved from 69% to 89% by the 23-day follow-up. Device interrogation
in the clinic showed overall improvement in atrial threshold of 0.5 V at 0.4 ms, sensing
at 4.1 mV, and impedance of 370 ohms; and ventricular threshold of 0.5 V at 0.4 ms,
sensing at 16.9 mV, and impedance of 620 ohms.
Discussion
This case demonstrates the unique programming of Aveir DR dual-chamber leadless pacemakers
to address intermittent loss of i2i wireless communication between atrial and ventricular
devices, with the goal of maintaining AV synchrony (atrial tracking and/or pacing)
when possible and providing uninterrupted ventricular demand pacing. In a preclinical
ovine study of the Aveir DR, i2i loss was uncommon and brief (<6 seconds) across a
variety of postures, daily activities, cardiac rhythms (sinus rhythm and induced AV
block), and heart rates, both acutely and chronically (up to 23 weeks postimplant).
4
A problem comparable to i2i loss with conventional transvenous pacemakers may be lead
dislodgement or fracture with transient or permanent issues with sensing and/or capture.
Transvenous devices cannot switch functional pacing modes to compensate for transient
sensing and pacing issues. They respond to oversensing/undersensing and failure to
capture within the constraints of the currently programmed pacing mode. In transvenous
devices, automatic mode switching only occurs in the setting of paroxysmal atrial
tachyarrhythmias to avoid atrial-triggered rapid ventricular pacing. The pacemaker
reprograms itself from a tracking mode, eg, DDD(R), to a no-tracking mode, eg, DDI(R),
thereby avoiding tracking of rapid atrial rates during atrial fibrillation or flutter.
The device reverts to a tracking mode when the atrial tachyarrhythmia terminates.
In contrast, the Aveir DR continuously assesses i2i communication on a beat-by-beat
basis and is programmed to rapidly switch functional pacing modes to address transient
losses of i2i communication, thereby avoiding ventricular underpacing.
This case demonstrates previously undescribed ECG patterns related to novel programming
and function of dual-chamber leadless pacemakers. New ECG patterns may become more
prevalent with widespread use of these devices. Accurate recognition and interpretation
of these new ECG patterns is required for the clinician to understand the clinical
relevance of changes in pacemaker behavior, and to determine if this is appropriate
behavior or requires intervention.